Drug Discovery World

AUGUST 1, 2023

Partnerships Earlier this year cell-engineering company MaxCyte signed a strategic platform license (SPL) with biotechnology company Catamaran Bio. In return MaxCyte will receive platform licensing fees and program-related revenue.

Drugs 130

Drugs Licensing Licensing Engineering 130

The Pharma Data

JANUARY 17, 2021

18 , 2021 /PRNewswire/ — Hanmi Pharmaceutical Co., plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields.

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

Drug Discovery World

AUGUST 12, 2022

Pfizer has launched a Phase III clinical trial of a vaccine to protect people against Lyme disease, in collaboration with pharmaceutical company Valneva. . The trial will enrol up to 6,000 participants aged five years and older and will be conducted across 50 sites where Lyme disease is highly endemic. Official comments .

Vaccine 130

Vaccine Disease Trials Pharmaceutical Companies 130

Drug Discovery World

JANUARY 31, 2023

But first, there is the urgency of getting the new drug application (NDA) or biologics license application (BLA) filing into the hands of the respective regulatory authorities. Biopharmaceutical Lifecycle Management (BPLM) is key to delivering novel therapies and lifesaving drugs to the world.

Production 246

Production Engineering Pharmaceutical Companies Clinical Trials 246

Drug Discovery World

MARCH 7, 2023

She has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing. Dr Janette Thomas, CEO, Five Alarm Bio Five Alarm Bio is an anti-ageing therapeutics company, which completed a seed investment round in early 2023.

International 246

International Science Pharmaceuticals DNA 246

Drug Discovery World

OCTOBER 16, 2023

The campus is home to GSK, the Cell and Gene Therapy Manufacturing Catapult, LifeArc and Cytiva, alongside a growing cluster of start-up companies which together have raised £2.9 Next, Saleko highligts how Northumberland and the North East of the UK are recognised for pharmaceutical manufacturing prowess. billion in funding.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

Crown Bioscience

MAY 4, 2021

Among the 180+ cancer drugs approved by the FDA since 1995, only 14 have been approved for pediatric use, with another 26 used off-label (i.e. used in a way that is not described in the license), and only three drugs have been approved exclusively for use in children.

Research 52

Research Pharmaceutical Companies Licensing Licensing 52

Drug Discovery World

AUGUST 3, 2023

There are also three synthetic cannabis-related drug products, which are Marinol (dronabinol), Syndros (dronabinol), and Cesamet (nabilone). Even still, these approved drug products require a licensed healthcare provider’s prescription. Jazz Pharmaceuticals has supplied the cannabidiol for the trials at no cost.

Clinical Trials 130

Clinical Trials Regulations Production FDA 130

Drug Target Review

SEPTEMBER 19, 2024

Could you give us an overview of IRLAB’s current drug development pipeline? According to IRLAB’s calculations, the probability that an ISP-generated drug will reach pivotal Phase III studies is almost three times higher than for a drug developed with traditional methods – 20 percent compared to seven percent.

Disease 52

Disease Drugs Treatment Drug Development 52

The Pharma Data

JANUARY 27, 2021

28, 2021 /PRNewswire/ — CASI Pharmaceuticals (Formerly Known As EntreMed, Inc.). The Company’s validated, proprietary F.I.R.S.T About CASI Pharmaceuticals. CASI Pharmaceuticals, Inc. SOURCE CASI Pharmaceuticals, Inc. ROCKVILLE, Md. ,

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

The Pharma Data

DECEMBER 9, 2020

Under its ongoing collaboration and license agreement, Crescendo’s proprietary transgenic platform and engineering expertise is being used to build Humabody ® -based therapeutics against certain targets selected by Takeda. This is the sixth technical milestone achieved by Crescendo in its collaboration with Takeda.

Licensing 52

Licensing Licensing Pharmaceutical Companies Engineering 52

Drug Target Review

FEBRUARY 1, 2024

But commitment to neuroscience drug development is critically important given the significant unmet medical needs and the ways in which patients, caregivers, and families suffer. As soon as drug developers can begin to develop conviction, momentum increases. It’s a great example of how our model works.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

Molecule Blog

JANUARY 9, 2023

IP-NFTs upgrade our legacy intellectual system by unifying IP (patents, legal), underlying data (through decentralized storage and access control), and economics (royalties, license fees, sales) into one programmable, transactable, digital unit. ‍ How will IP-NFTs enable drug development in the future?

Research 52

Research Licensing Licensing Science 52

Molecule Blog

AUGUST 19, 2021

In drug development however, when a therapeutic is discovered, or research becomes more akin to product development, the source of funding must change. In a best case scenario, that technology is out-licensed to a pharmaceutical company and the remainder of the development carries on there.

Research 52

Research Licensing Licensing Drug Development 52

The Pharma Data

DECEMBER 8, 2020

AbCellera’s AI-powered antibody discovery platform speeds the otherwise lengthy and grueling process by analyzing the database of natural immune systems to find antibodies that can be developed into drugs. Tackle the toughest problems in drug development.” SciNeuro Pharmaceuticals . Reduce cost. Nuance Pharma .

RNA 52

RNA Protein Expression Therapies Disease 52

Drug Discovery World

OCTOBER 10, 2022

Will an expansion in the use of effective digital biomarkers help improve the productivity of drug development in neuroscience? Increasingly, digital biomarkers are becoming more effectively used in the discovery and development of drugs that act in the central nervous system.

Drug Development 130

Drug Development Clinical Trials Drugs Trials 130

Drug Discovery World

MARCH 6, 2024

Precision neuroscience has similar potential to revolutionise neurological drug development, but it requires a different way of thinking about disease than we usually apply in oncology. All this is of huge interest when you’re putting a new drug on the market and working inside an outcomes-based remuneration model.

Clinical Trials 162

Clinical Trials Pharmaceutical Companies Disease Trials 162

The Pharma Data

JANUARY 24, 2021

The company has established a diversified R & D pipeline comprising 27 innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases.

FDA 52

FDA Clinical Trials Trials Treatment 52

The Pharma Data

NOVEMBER 6, 2020

With the opinions expressed at the Advisory Committee and the data presented, the FDA will continue the review process with a decision on whether to approve the aducanumab Biologics License Application by March 7, 2021. . Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement.

Disease 40

Disease FDA Clinical Trials Licensing 40

The Pharma Data

SEPTEMBER 8, 2020

Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. For more information, please visit [link]. Learn more at Learn more at www.jnj.com.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

OCTOBER 29, 2020

Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement. have collaborated on the development and commercialization of aducanumab globally. is a leading global pharmaceutical company headquartered in Japan. Since October 2017 Biogen and Eisai Co., About Eisai Co.,

Marketing 40

Marketing Disease Clinical Trials Treatment 40

The Pharma Data

SEPTEMBER 8, 2020

Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech. and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. About the Janssen Pharmaceutical Companies of. Bayer Animal Health.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

DECEMBER 9, 2020

Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement. have collaborated on the development and commercialization of aducanumab globally. is a leading global pharmaceutical company headquartered in Japan. Since October 2017 Biogen and Eisai Co., About Eisai Co.,

Clinical Trials 40

Clinical Trials Drugs Disease Licensing 40

Drug Discovery World

MAY 11, 2023

The drug has already shown particular promise in ovarian cancer in a first-in-human, Phase I trial led by researchers at the ICR and The Royal Marsden NHS Foundation Trust. Algok Bio’s exclusive license agreement with BTG grants the former the rights to develop and commercialise idetrexed worldwide.

Trials 130

Trials Small Molecule Drugs Pharmaceutical Companies 130

Advarra

AUGUST 10, 2023

The Orphan Drug Act creates incentives for developing orphan drugs to treat such diseases. Operation Warp Speed for Rare Diseases looks to accelerate both drug development and approval. The post Operation Warp Speed for Rare Diseases: Expected Boom in Drug Development and Approval appeared first on Advarra.

Drug Development 52

Drug Development Disease Engineering Therapies 52

Codon

SEPTEMBER 29, 2024

It wasn’t a silver bullet to the hard problem of drug development, but it wasn’t too far off either. At best, the corporations with the best models released weak versions to the public under non-commercial licenses. For a small, elite cadre of companies, animal experiments became obsolete.

Engineering 125

Engineering Virus DNA Therapies 125

Altus Drug Development

MAY 31, 2022

Oral formulation is the development and manufacturing of pharmaceuticals designed for oral delivery. Drugs introduced to the body through oral delivery are absorbed by the stomach, intestine, or gastrointestinal tract. Common examples of oral drug delivery systems include tablets and capsules.

Pharmaceuticals 52

Pharmaceuticals Drug Development Production Pharmaceutical Companies 52

Codon

FEBRUARY 13, 2024

Phage-based products have been licensed for use as antibacterial agents in the sanitation , food production , and animal health industries. The weakened dose of phages helped bacteria develop resistance, and the trial became yet another study that provided evidence phages are safe, but little more.

Therapies 118

Therapies Virus DNA Clinical Trials 118

NIH Director's Blog: Drug Development

FEBRUARY 27, 2018

More than 90 percent of that contributory research was basic—that is, related to the discovery of fundamental biological mechanisms, rather than actual development of the drugs themselves. Previous attempts to quantify the contribution of federal funding to new drug development had looked primarily at patents.

Research 52

Research Science FDA Pharmaceutical Companies 52

Molecule Blog

MARCH 17, 2023

The Primitives of Biomedical Discovery and Development It’s noteworthy that the majority of approved medicines, around 60%, have their roots in academia, with the remaining 40% stemming from pharmaceutical research and discovery. These studies involve more in vivo testing in increasingly larger animals to evaluate safety and efficacy.

Engineering 52

Engineering Research Government Clinical Trials 52

The Pharma Data

NOVEMBER 15, 2020

Kalin was a partner in the global healthcare practice of McKinsey & Company, from 1990-2002. Her healthcare experience spans diagnostics, medical devices, pharmaceuticals, and digital health. Wasman was with Schering-Plough Corporation, a global pharmaceutical company, for over eight years, holding various U.S.

Clinical Trials 40

Clinical Trials Trials Production International 40

The Pharma Data

OCTOBER 27, 2020

Novartis has been granted an option to in-license global rights of MP0420 and MP0423 – multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19. The company has compounds in various stages of clinical and preclinical development with a focus on oncology.

Therapies 52

Therapies Virus Treatment Clinical Trials 52

Agency IQ

OCTOBER 27, 2023

Date What’s Happening Explanation Source October 31 FDA deadline on Florida drug importation plan The FDA has said in court filings that it plans to make a ruling on Florida’s prescription drug importation plan by October 31. The following PDUFA dates were obtained from publicly available sources.

FDA 40

FDA Science Regulations Production 40

Drug Discovery World

NOVEMBER 10, 2023

AH : I am Chief Business Officer for Antibody Analytics, a collaborative immunology CRO, specialising in supporting immunotherapy developers at the discovery to pre-clinical stages of the drug development process. I have now been with Antibody Analytics for three and half years. MT: Who or what inspires you?

Molecular Biology 147

Molecular Biology Clinical Trials Licensing Licensing 147

The Pharma Data

DECEMBER 15, 2020

(NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company’s business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

Clinical Trials 52

Clinical Trials Trials Treatment Therapies 52

The Pharma Data

DECEMBER 30, 2020

In short, the advisory committee did not vote to recommend the drug to the agency, which has a PDUFA date of March 7, 2021 to decide whether to approve the aducanumab Biologics License Application (BLA). Biden Administration and drug pricing. Four big companies are cited as possible tasty takeover targets for 2021.

Vaccine 52

Vaccine FDA Trials Therapies 52